[Clinical applications of recombinant complement inhibitors]

Area of Science:

• The complement system is a key component of the innate immune system.
• It comprises soluble and membrane-bound proteins that regulate immune responses.

Context:

• Complement activation generates anaphylatoxins (C3a, C4a, C5a) and the membrane attack complex.
• These mediators drive acute inflammation and cell lysis but can cause host cell damage due to lack of self/non-self discrimination.
• Dysregulated complement activation is implicated in numerous diseases.

Purpose:

• To explore the role of complement inhibitors in managing diseases caused by inappropriate complement activation.
• To discuss the production of recombinant complement inhibitors using eukaryotic or prokaryotic systems.

Summary:

• The complement system, while vital for immunity, requires strict regulation by inhibitors to prevent self-damage.
• Inappropriate activation contributes to disease pathogenesis.
• Recombinant complement inhibitors offer therapeutic potential and can be manufactured using diverse expression platforms.

Impact:

• Understanding complement regulation is crucial for developing targeted therapies.
• Recombinant protein production technologies enable large-scale manufacturing of therapeutic complement inhibitors.
• The choice of expression system impacts protein functionality due to post-translational modifications.